These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Stroman DW; Dajcs JJ; Cupp GA; Schlech BA Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308 [TBL] [Abstract][Full Text] [Related]
3. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. McCulley JP; Caudle D; Aronowicz JD; Shine WE Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244 [TBL] [Abstract][Full Text] [Related]
5. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. Segreti J; Jones RN; Bertino JS J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341 [TBL] [Abstract][Full Text] [Related]
6. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309 [TBL] [Abstract][Full Text] [Related]
7. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. Morrissey I; Burnett R; Viljoen L; Robbins M J Infect; 2004 Aug; 49(2):109-14. PubMed ID: 15236917 [TBL] [Abstract][Full Text] [Related]
8. Ophthalmic infections and their anti-infective challenges. Alfonso E; Crider J Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S1-6. PubMed ID: 16257307 [TBL] [Abstract][Full Text] [Related]
9. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523 [TBL] [Abstract][Full Text] [Related]
10. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Scoper SV Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691 [TBL] [Abstract][Full Text] [Related]
11. Safety of moxifloxacin as shown in animal and in vitro studies. McGee DH; Holt WF; Kastner PR; Rice RL Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310 [TBL] [Abstract][Full Text] [Related]
12. [Fluoroquinolones in ophthalmology: indications and current use]. Chiquet C; Labetoulle M J Fr Ophtalmol; 2008 Oct; 31(8):803-8. PubMed ID: 19107048 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of sparfloxacin eye drop in the management of conjunctival and corneal infection. Vyas U; Desai T; Shah C J Indian Med Assoc; 2002 Jun; 100(6):398-9. PubMed ID: 12416674 [TBL] [Abstract][Full Text] [Related]
17. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits. Proksch JW; Ward KW J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668 [TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis. Hyon JY; Joo MJ; Hose S; Sinha D; Dick JD; O'Brien TP Arch Ophthalmol; 2004 Aug; 122(8):1166-9. PubMed ID: 15302657 [TBL] [Abstract][Full Text] [Related]
19. Risk factors for fluoroquinolone resistance in ocular cultures. Lee J; Choi S Korean J Ophthalmol; 2015 Feb; 29(1):7-13. PubMed ID: 25646055 [TBL] [Abstract][Full Text] [Related]